Beigene Ltd Company Profile (NASDAQ:BGNE)

About Beigene Ltd

Beigene Ltd logoBeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BGNE
  • CUSIP:
Key Metrics:
  • Previous Close: $29.41
  • 50 Day Moving Average: $28.09
  • 200 Day Moving Average: $28.68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.38
  • P/E Growth: 0.00
  • Market Cap: $923.26M
  • Outstanding Shares: 32,903,000
Additional Links:
Companies Related to Beigene Ltd:

Analyst Ratings

Consensus Ratings for Beigene Ltd (NASDAQ:BGNE) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.67 (41.67% upside)

Analysts' Ratings History for Beigene Ltd (NASDAQ:BGNE)
DateFirmActionRatingPrice TargetDetails
6/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/8/2016Morgan StanleyBoost Price Target$39.00 -> $42.00View Rating Details
2/29/2016Robert W. BairdInitiated CoverageOutperform$44.00View Rating Details
2/29/2016Goldman Sachs Group Inc.Initiated CoverageBuy$33.00View Rating Details
(Data available from 8/24/2014 forward)


Earnings History for Beigene Ltd (NASDAQ:BGNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Beigene Ltd (NASDAQ:BGNE)
Current Year EPS Consensus Estimate: $-3.39 EPS
Next Year EPS Consensus Estimate: $-3.34 EPS


Dividend History for Beigene Ltd (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Beigene Ltd (NASDAQ:BGNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Beigene Ltd (NASDAQ:BGNE)
DateHeadline logoBeiGene Approved To Start Clinical Trials In China (NASDAQ:BGNE) - August 23 at 5:29 AM logoBeiGene (BGNE) Approved by China FDA to Commence BGB-290 Clinical Trials (NASDAQ:BGNE) - August 18 at 9:19 PM logoBeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290 (NASDAQ:BGNE) - August 18 at 12:13 PM logoBeiGene Reports Second Quarter 2016 Financial Results (NASDAQ:BGNE) - August 10 at 9:16 PM logoTop Gainers, Losers in Manufacturing Sector Today (NASDAQ:BGNE) - July 23 at 8:03 AM logoBeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China (NASDAQ:BGNE) - July 5 at 4:41 PM logoProfile: BeiGene Ltd (BGNE.OQ) (NASDAQ:BGNE) - July 3 at 8:33 AM
News IconHavre de Grace’s Independence Celebrations set for this weekend (NASDAQ:BGNE) - July 1 at 8:59 PM
News IconBaltimore Hospital finds alternative medevac site (NASDAQ:BGNE) - July 1 at 8:59 PM
News IconAll Food Will be Local For First Time in Artscape History (NASDAQ:BGNE) - July 1 at 8:59 PM
News IconCelebrate Independence Day at the Inner Harbor (NASDAQ:BGNE) - July 1 at 8:59 PM
News IconThe Arc Baltimore Names BGE's Larry Burley to its Board of Directors (NASDAQ:BGNE) - July 1 at 8:59 PM logoBeigene Ltd (NASDAQ:BGNE) Doses First Patient In Combination Trial Of BGB-A317 and BGB-3111 (NASDAQ:BGNE) - July 1 at 8:59 PM
News IconBGE restores ospreys' home after a lighting strike destroys their nest (NASDAQ:BGNE) - July 1 at 8:59 PM
News IconBGE Inks Medevac Helicopter Deal with Baltimore Hospital (NASDAQ:BGNE) - July 1 at 8:59 PM
News IconBGE customers can join texting program for outages (NASDAQ:BGNE) - July 1 at 8:59 PM logoBeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 (NASDAQ:BGNE) - June 29 at 4:51 PM logoU.S. regulator says too many drugmakers chasing same cancer strategy (NASDAQ:BGNE) - June 14 at 4:44 PM logoBeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting (NASDAQ:BGNE) - June 5 at 9:08 AM logoBeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting (NASDAQ:BGNE) - May 19 at 6:52 AM logoBEIGENE, LTD. Files SEC form 10-Q, Quarterly Report (NASDAQ:BGNE) - May 12 at 4:25 PM logoBeiGene Reports First Quarter 2016 Financial Results (NASDAQ:BGNE) - May 11 at 5:07 PM logoBeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development (NASDAQ:BGNE) - May 4 at 5:41 PM logoChinese Commodities Brokerage Yintech Debuts on Nasdaq (NASDAQ:BGNE) - April 28 at 8:03 AM logoOpening Bell, April 21, 2016 (NASDAQ:BGNE) - April 21 at 9:30 AM logoBeiGene (Nasdaq: BGNE) to Ring The Nasdaq Stock Market Opening Bell (NASDAQ:BGNE) - April 20 at 10:21 AM logoBeiGene Ltd. :BGNE-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:BGNE) - April 19 at 9:26 AM
News IconThe 11 year-old Dancing Trumps from Fiske Elementary School in Wellesley, Massachusetts were banned from entering the talent show (NASDAQ:BGNE) - April 18 at 7:44 AM logoBEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BGNE) - April 18 at 7:40 AM logoBeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting (NASDAQ:BGNE) - April 17 at 5:26 PM logoBEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati (NASDAQ:BGNE) - April 11 at 5:10 PM logoBeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer (NASDAQ:BGNE) - April 11 at 5:00 PM logoBEIGENE, LTD. Financials (NASDAQ:BGNE) - April 5 at 1:04 PM logoWith Biotechnology Companies Leading the Way, Six Venture-Backed IPOs Recorded in First Quarter (NASDAQ:BGNE) - April 4 at 4:45 PM logoEarnings Reported After The Bell Mar.30 (NASDAQ:BGNE) - March 31 at 7:23 AM logoBEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:BGNE) - March 30 at 4:24 PM logoBeiGene Reports Fourth Quarter and Full Year 2015 Financial Results (NASDAQ:BGNE) - March 30 at 4:05 PM logoBEIGENE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:BGNE) - March 29 at 4:17 PM logoBeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting (NASDAQ:BGNE) - March 16 at 5:48 PM logo8:02 am BeiGene recieves clinical trial application approval from CFDA to conduct clinical trials with BGB-3111 (NASDAQ:BGNE) - March 7 at 8:02 AM logoBeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 (NASDAQ:BGNE) - March 7 at 8:00 AM logoBeiGene to Present at Cowen and Company 36th Annual Health Care Conference (NASDAQ:BGNE) - March 1 at 8:00 AM logoMorgan Stanley: Buy BeiGene's Global Upside (NASDAQ:BGNE) - February 29 at 3:33 PM logoStreet Talk: CLR, HLT, BGNE, NFX & FET (NASDAQ:BGNE) - February 29 at 2:25 PM logoCoverage initiated on BeiGene by Robert W. Baird, Goldman and Morgan Stanley (NASDAQ:BGNE) - February 29 at 6:46 AM logo13D Filing: Baker Bros. Advisors and Beigene, Ltd. (BGNE) (NASDAQ:BGNE) - February 22 at 4:04 PM logo13D Filing: Billionaire Lei Zhang’s Hillhouse Capital Management Reports Stake in Beigene, Ltd. (BGNE) (NASDAQ:BGNE) - February 22 at 12:03 PM logoNo Relief in Sight for IPO Market --Morning MoneyBeat (NASDAQ:BGNE) - February 12 at 8:04 AM logoBill Gates’ Cascade Investment Boosts AutoNation Inc. (AN) Stake, Buffett Keeps Buying Phillips 66 (PSX), Plus Baker Bros.’ Latest Move (NASDAQ:BGNE) - February 10 at 12:39 PM logoLittle Hope For IPO Recovery In First Quarter (NASDAQ:BGNE) - February 9 at 11:04 AM


Beigene Ltd (NASDAQ:BGNE) Chart for Wednesday, August, 24, 2016

Last Updated on 8/24/2016 by Staff